Telix Acquires ITM Isotope for $1.65 Billion in Strategic Radiopharma Expansion
Australian biotechnology firm Telix Pharmaceuticals has agreed to acquire German isotope producer ITM Isotope for approximately $1.65 billion, as announced on Monday by both companies. The acquisition aims to bolster Telix’s position in the radiopharmaceutical sector and enhance its vertical integration capabilities across production and distribution of medical isotopes. The deal reflects a strategic move to strengthen Telix's foothold in the growing market for targeted alpha therapy (TAT) and other advanced nuclear medicine treatments. ITM Isotope is known for producing actinium-225, a key isotope used in TAT development. The acquisition aligns with increasing global demand for precision oncology therapies. The transaction underscores Telix’s commitment to expanding its end-to-end capabilities from isotope production through radiopharmaceutical manufacturing and clinical application.
Topics: Biotechnology International Expansion Radiopharmaceuticals